NodThera

NodThera is a clinical-stage biotech pioneering the development of NLRP3 inflammasome inhibitors for chronic inflammatory diseases. The company is leveraging a growing body of scientific evidence that positions NLRP3 as a key upstream catalyst in inflammation, aiming to create treatments for a broad range of conditions affecting the body and brain, including cardiovascular disease and neuroinflammation. Led by an experienced team of industry veterans, NodThera is advancing a portfolio of small molecule candidates. As a private company, it is positioned in a competitive but high-potential area of immunology and inflammasome biology.

Discovery and development of orally available, brain-penetrant small molecule inhibitors targeting the NLRP3 inflammasome, an upstream driver of chronic inflammation.

The NLRP3 inhibitor space is competitive, with several large pharmaceutical companies (e.g., Roche/Inflazome, Novartis) and biotechnology firms actively developing candidates. Differentiation will depend on clinical efficacy, safety profile, pharmacokinetic properties (especially brain penetration), and speed of development.